Abstract
Introduction: Letrozole is a third-generation selective aromatase inhibitor and an effective agent for ovulation induction. Even though it was used in Clomiphene Citrate failure cases, Clomiphene Citrate resistant women, for Intra-Uterine insemination, and also for mild stimulation for IVF/ICSI cases it has not gained its importance as a first-line drug for ovulation induction. Objective: To study the effectiveness of two different doses of Letrozole in ovulation induction and pregnancy rates and to calculate the proportion of Letrozole resistant and failure cases. Materials and Methods: One year Prospective, observational study was conducted on 120 study participants who were divided into two groups and were given either 2.5 or 5 mg of Letrozole respectively. Serial Ultrasound scans were done from day 10 to assess response to two doses of Letrozole. Results: It was observed that 28 (46.67%) of 60 study participants in group I and 38 (63.33%) of 60 study participants in group II had ovulated. Conclusion: It is observed that there was no significant statistical difference in ovulation rates, Letrozole failure, and resistance rates in both groups. Though the endometrial growth was comparable in both study groups, it was observed that there was better follicular growth in study group II. The study group also showed a statistically significant difference in the pregnancy rates compared to group I. Therefore 5mg dosage of Letrozole could be recommended for ovulation induction.
Highlights
IntroductionLetrozole is a third-generation selective aromatase inhibitor and an effective agent for ovulation induction
Letrozole is a third-generation selective aromatase inhibitor and an effective agent for ovulation induction. Even though it was used in Clomiphene Citrate failure cases, Clomiphene Citrate resistant women, for Intra-Uterine insemination, and for mild stimulation for IVF/ICSI cases it has not gained its importance as a first-line drug for ovulation induction
A prospective, observational study was conducted on 120 study participants who were divided into two groups Group I (2.5mg) and Group II (5mg) and was given 2.5 mg or 5 mg of Letrozole respectively
Summary
Letrozole is a third-generation selective aromatase inhibitor and an effective agent for ovulation induction. Even though it was used in Clomiphene Citrate failure cases, Clomiphene Citrate resistant women, for Intra-Uterine insemination, and for mild stimulation for IVF/ICSI cases it has not gained its importance as a first-line drug for ovulation induction. The major causes of infertility include ovulatory dysfunction (20-40%), tubal and peritoneal pathology (30-40%), and male factors (30-40%). Ovulatory dysfunction is more common in younger than in older couples, tubal and peritoneal factors have a similar prevalence, and male factors and unexplained infertility are observed somewhat more often in older couples [4,5]. The most common cause among ovarian factors is anovulation, and PCOS stands first in them
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Obsgyne Review Journal of Obstetric and Gynecology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
